

Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



Research Infrastructures and COVID-19 Research

Responses to the questionnaire

IRTA-CReSA

IRTA-CReSA is a public research institute devoted to research in animal health following the One Health concept.

SERVICE/S IMPLEMENTED

Services to public stakeholders and also private companies in animal health field but also human health, animal models for human infectious diseases, inactivation viral studies, antiviral assays, and vaccine development and testing

▪ What stage in COVID-19 intervention your RI is addressing?

Yes, we have several possibilities to support research on COVID-19:

- SARS-CoV-2 isolation
- In vitro studies of anti-viral and antibody efficacy
- In vivo studies of anti-viral, antibody and vaccine efficacy (not yet in place, waiting for the hACE2 transgenic mice availability)
- Antiviral, antibody and vaccine research
- Animal infection model development

▪ Instruments/databases involved:

BSL3 large animal and laboratory facilities

▪ How is the proposal submitted?

<http://www.rlasb.es/protocolo-de-acceso/?lang=en>

▪ Who evaluates the proposal?


Access committee

▪ Is the submission continuous, or linked to a deadline?

Continuous

▪ What is the estimated time from the submission to the access / service provision?

no answer



Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



CHARACTERISTICS OF THE ACCESS

Restrictions: no restrictions

Comment for remote access only: IRTA-CReSA

| | |
|--|-----|
| Analytical Facilities: If on-site access is allowed, is mobility support available? | NO |
| All RIs: Is the access free for non-proprietary research? | NO |
| All RIs: Is commercial access available at reduced prices? | YES |
| Analytical Facilities: Are there limitations regarding the type of samples? | NO |
| Analytical Facilities: Are there special requirements for shipment of the samples? | YES |
| Analytical Facilities: Are there specific requirements regarding the preparation or handling of the samples? | YES |

Additional comments related to the questions above: The mandatory requirements of category A and B following IATA regulations. Moreover, non-inactivated samples only can be shipped to equivalent High Containment Facility. The maximum biosafety level allowed is BSL3, also called High Containment, for Animal and Human viruses and bacteria, independent of the size of the animal model (small laboratory animal but also farm animal). We can provide shipment of inactivated samples if they have to be handled in BSL2 environments or non-inactivated (viable) samples if they will be further processed only if BSL3 environment is granted. Any time fulfilling IATA and UN regulations regarding proper shipping, labelling and marking.

ACCESSIBILITY OF THE PUBLICATION AND DATA

| | |
|---|------------------------|
| Is there any requirement to publish in open access journals? | NO |
| Is the data generated associated to metadata and is it publicly available? | NO |
| Where is the data or metadata published? (e.g. in the institution's catalogue, in other open data repositories, etc). | open data repositories |